Market Overview

Teva, Mylan Settle Copaxone Patent Litigation in France, UK, Netherlands

Related TEVA
AxoGen (AXGN) in Focus: Stock Moves 5.7% Higher - Tale of the Tape
Is Biogen (BIIB) Poised to Beat Earnings Estimates? - Analyst Blog
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)

Teva Pharmaceutical Industries (NYSE: TEVA) and Mylan Inc. (NASDAQ: MYL)
today announce that certain of their affiliates have agreed to settle
and dismiss pending patent litigation involving Copaxone® (glatiramer
acetate) in the United Kingdom, the Netherlands and France relating to
non-infringement and the validity of European Patent 0,762,888, which
expires in May 2015. The terms of the settlement are confidential.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's

See full press release

Posted-In: News Guidance Financing Offerings Contracts Legal Global

 

Most Popular

Related Articles (MYL + TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free